Pharmaceutical Innovation


Right now, it’s arguable that government ground rules give pharmaceutical companies too little incentive to innovate.  If FDA regs forced them to demonstrate more than just superiority to a sugar pill, drug company incentives might be aligned a little more strongly toward finding genuinely effective new therapies instead of yet another statin or ED pill or a slightly different heartburn formulation.

Or maybe not.  It’s an argument worth having.  But the current system is by no means the free market juggernaut conservatives like to pretend it is.  Changing the ground rules might very well increase innovation, not stifle it.

Fact:

Mother Jones was founded as a nonprofit in 1976 because we knew corporations and the wealthy wouldn’t fund the type of hard-hitting journalism we set out to do.

Today, reader support makes up about two-thirds of our budget, allows us to dig deep on stories that matter, and lets us keep our reporting free for everyone. If you value what you get from Mother Jones, please join us with a tax-deductible donation so we can keep on doing the type of journalism that 2018 demands.

Donate Now